Pao, W. & Chmielecki, J.: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.Nat. Rev. Cancer, 10, 760-774 (2010)[PubMed]
Piotrowska, Z. & Sequist. L. V.: Treatment of EGFR-mutant lung cancers after progression in patients receiving first-line EGFR tyrosine kinase inhibitors.JAMA Oncol., 2, 948-954 (2016)[PubMed]
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. et al.: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N. Engl. J. Med., 366, 2455-2465 (2012)[PubMed]
Topalian, S. L., Hodi, F. S., Brahmer, J. R. et al.: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N. Engl. J. Med., 366, 2443-2454 (2012)[PubMed]
Carbone, D. P., Reck, M., Paz-Ares, L. et al.: First-line nivolumab in stage IV or recurrent non-small-cell lung cancer.N. Engl. J. Med., 376, 2415-2426 (2017)[PubMed]
Rizvi, N. A., Hellmann, M. D., Snyder, A. et al.: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science, 348, 124-128 (2015)[PubMed]
Gettinger, S., Horn, L., Jackman, D. et al.: Five-year follow-up of nivolumab in previously treated Aadvanced non-small-cell lung cancer: results from the CA209-003 study.J. Clin. Oncol., DOI: 10.1200/JCO.2017.77.0412[PubMed]
Chen, D. S. & Mellman, I.: Elements of cancer immunity and the cancer-immune set point.Nature, 541, 321-330 (2017)[PubMed]
Borghaei, H., Paz-Ares, L., Horn, L. et al.: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N. Engl. J. Med., 373, 1627-1639 (2015)[PubMed]
Reck, M., Rodriguez-Abreu, D., Robinson, A. G. et al.: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.N. Engl. J. Med., 375, 1823-1833 (2016)[PubMed]
Tumeh, P. C., Harview, C. L., Yearley, J. H. et al.: PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature, 515, 568-571 (2014)[PubMed]
Rizvi, H., Sanchez-Vega, F., La, K. et al.: Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing.J. Clin. Oncol., 36, 633-641 (2018)[PubMed]
Koyama, S., Akbay, E. A., Li, Y. Y. et al.: STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment.Cancer Res., 76, 999-1008 (2016)[PubMed]
Chowell, D., Morris, L. G. T., Grigg, C. M. et al.: Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.Science, 359, 582-587 (2018)[PubMed]
Routy, B., Le Chatelier, E., Derosa, L. et al.: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science, 359, 91-97 (2018)[PubMed]
Mariathasan, S., Turley, S. J., Nickles, D. et al.: TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature, 554, 544-548 (2018)[PubMed]
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. et al.: Primary, adaptive, and acquired resistance to cancer immunotherapy.Cell, 168, 707-723 (2017)[PubMed]
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S. et al.: Mutations associated with acquired resistance to PD-1 blockade in melanoma.N. Engl. J. Med., 375, 819-829 (2016)[PubMed]
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H. et al.: Primary resistance to PD-1 blockade mediated by JAK1/2 mutations.Cancer Discov., 7, 188-201 (2017)[PubMed]
Gettinger, S., Choi, J., Hastings, K. et al.: Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer.Cancer Discov., 7, 1420-1435 (2017)[PubMed]
Koyama, S., Akbay, E. A., Li, Y. Y. et al.: Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Nat. Commun., 7, 10501 (2016)[PubMed]
Imaizumi, T., Kumagai, M., Sasaki, N. et al.: Interferon-γ stimulates the expression of galectin-9 in cultured human endothelial cells.J. Leukoc. Biol., 72, 486-491 (2002)[PubMed]